关于《PARP抑制剂相关性骨髓异常增生综合征和急性髓细胞性白血病:随机对照试验的安全性荟萃分析和WHO药物警戒数据库的回顾性研究》的解读

Interpretation of Myelodysplastic syndrome and acute myeloidleukaemia in patients treated with PARP inhibitors:a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database

多腺苷二磷酸核糖聚合酶[poly(ADP-ribose)polymerase,PARP]抑制剂在多个瘤种,特别是卵巢癌中显示出确切的有效性和可靠的安全性。然而,一些罕见和迟发的不良事件,包括骨髓异常增生综合征(myelodysplastic syndrome,MDS)和急性髓细胞性白血病(acute myelogenous leukemia,AML)病例的出现提示研究者和临床医生必须提高警惕。由于此类不良反应发生率低,Morice等通过系统回顾和安全性荟萃分析,以评估与PARP抑制剂相关的MDS和AML的发生风险和发病率。并通过对世界卫生组织药物警戒数据库(VigiBase)进行分析,了解与PARP抑制剂相关的MDS和AML病例的临床特征。笔者对该研究进行了解读,以帮助临床医生更好地了解PARP抑制剂迟发性血液毒性并及时识别与处理。

Poly(ADP-ribose)polymerase(PARP)inhibitors have shown efficacy and acceptable safety in a range of neoplasms,particularly in ovarian cancers.However,some concerns have emerged regarding rare and delayed adverse events including cases of myelodysplastic syndrome(MDS)and acute myelogenous leukemia(AML).Because of the low incidence of MDS and AML in patients treated with PARP inhibitors,the study leaded by Morice was to estimate the risk of MDS and AML related to PARP inhibitors,via a systematic review and safety meta-analysis,and to describe clinical features of PARP inhibitors related MDS and AML cases reported in WHO’s pharmacovigilance database(VigiBase).In this paper,we interpret the study for its better clinical application in evaluating delayed haematological toxicities in patients treated with PARP inhibitors.